Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

NCT01763164

Last updated date
Study Location
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Metastatic or Unresectable Cutaneous Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)

- Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory

- Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma

- Evidence of at least one measurable lesion as detected by radiological or photographic methods

- Adequate bone marrow, organ function, cardiac and laboratory parameters

- Normal functioning of daily living activities

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Any untreated CNS metastases


- Uveal or mucosal melanoma


- History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO


- Patients with washout period < 6 weeks from the last dose of ipilimumab or other
immunotherapy.


- Previous systemic chemotherapy for unresectable locally advanced or metastatic
melanoma.


- History of Gilbert's syndrome


- Prior therapy with a MEK- inhibitor


- Impaired cardiovascular function or clinically significant cardiovascular diseases


- Uncontrolled arterial hypertension despite medical treatment


- HIV positive or active Hepatitis A or B


- Impairment of gastrointestinal function


- Patients who have undergone major surgery or radiotherapy ≤ 3 weeks prior to starting
study drug or who have not recovered from side effects of such procedure;


- Patients with neuromuscular disorders that are associated with elevated CK.


- Pregnant or nursing (lactating) women


- Medical, psychiatric, cognitive or other conditions that may compromise the patient's
ability to understand the patient information, give informed consent, comply with the
study protocol or complete the study


Other protocol-defined inclusion/exclusion criteria may apply

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Metastatic or Unresectable Cutaneous MelanomaStudy Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
NCT01763164
  1. Fayetteville, Arkansas
  2. Rogers, Arkansas
  3. Altamonte Springs, Florida
  4. Bonita Springs, Florida
  5. Bradenton, Florida
  6. Brandon, Florida
  7. Cape Coral, Florida
  8. Clearwater, Florida
  9. Clearwater, Florida
  10. Fort Myers, Florida
  11. Fort Myers, Florida
  12. Gainesville, Florida
  13. Hudson, Florida
  14. Inverness, Florida
  15. Largo, Florida
  16. Largo, Florida
  17. Naples, Florida
  18. Naples, Florida
  19. New Port Richey, Florida
  20. Orange City, Florida
  21. Orlando, Florida
  22. Port Charlotte, Florida
  23. Saint Petersburg, Florida
  24. Saint Petersburg, Florida
  25. Sarasota, Florida
  26. Sarasota, Florida
  27. Spring Hill, Florida
  28. Tampa, Florida
  29. Tampa, Florida
  30. Tavares, Florida
  31. Venice, Florida
  32. Venice, Florida
  33. Niles, Illinois
  34. Park Ridge, Illinois
  35. Goshen, Indiana
  36. Bangor, Maine
  37. Baltimore, Maryland
  38. Boston, Massachusetts
  39. Boston, Massachusetts
  40. Boston, Massachusetts
  41. Bingham Farms, Michigan
  42. Detroit, Michigan
  43. Detroit, Michigan
  44. Farmington Hills, Michigan
  45. Omaha, Nebraska
  46. Hackensack, New Jersey
  47. Hackensack, New Jersey
  48. Voorhees, New Jersey
  49. Columbus, Ohio
  50. Columbus, Ohio
  51. Portland, Oregon
  52. Portland, Oregon
  53. Portland, Oregon
  54. Portland, Oregon
  55. Portland, Oregon
  56. Allentown, Pennsylvania
  57. Allentown, Pennsylvania
  58. Bethlehem, Pennsylvania
  59. Bethlehem, Pennsylvania
  60. Easton, Pennsylvania
  61. Hershey, Pennsylvania
  62. Philadelphia, Pennsylvania
  63. Philadelphia, Pennsylvania
  64. Quakertown, Pennsylvania
  65. Nashville, Tennessee
  66. Austin, Texas
  67. Dallas, Texas
  68. Dallas, Texas
  69. Dallas, Texas
  70. Dallas, Texas
  71. Dallas, Texas
  72. Dallas, Texas
  73. Dallas, Texas
  74. Fort Worth, Texas
  75. The Woodlands, Texas
  76. Buenos Aires, Ciudad Autónoma DE Buenosaires
  77. Viedma, RÍO Negro
  78. Rosario, Santa FE
  79. Buenos Aires,
  80. Camperdown, New South Wales
  81. Gateshead, New South Wales
  82. North Sydney, New South Wales
  83. Woolloongabba, Queensland
  84. Adelaide, South Australia
  85. Graz, Steiermark
  86. Innsbruck, Tirol
  87. Salzburg,
  88. Vienna,
  89. Wilrijk, Antwerpen
  90. Leuven,
  91. Liege,
  92. Passo Fundo, RIO Grande DO SUL
  93. Porto Alegre, RIO Grande DO SUL
  94. Rio de Janeiro,
  95. Sao Paulo,
  96. Edmonton, Alberta
  97. London, Ontario
  98. Toronto, Ontario
  99. Toronto, Ontario
  100. Montreal, Quebec
  101. Quebec,
  102. Brno, Jihomoravský KRAJ
  103. Ostrava,
  104. Praha 10,
  105. Praha 2,
  106. Angers, Maine-et-loire
  107. Lille, Nord
  108. Lyon, Rhône
  109. Bordeaux,
  110. Boulogne Billancourt,
  111. Le Mans,
  112. Marseille,
  113. Nice,
  114. Paris,
  115. Pierre Benite,
  116. Reims,
  117. Rouen,
  118. Freiburg im Breisgau, Baden-württemberg
  119. Mannheim, Baden-württemberg
  120. München, Bayern
  121. Regensburg, Bayern
  122. Würzburg, Bayern
  123. Frankfurt, Hessen
  124. Frankfurt, Hessen
  125. Buxtehude, Niedersachsen
  126. Minden, Nordrhein-westfalen
  127. Quedlinburg, Sachsen-anhalt
  128. Leipzig, Sachsen
  129. Berlin, Schleswig-holstein
  130. Erfurt, Thüringen
  131. Dresden,
  132. Essen,
  133. Gera,
  134. Hannover,
  135. Heidelberg,
  136. Kiel,
  137. Koeln,
  138. Lübeck,
  139. Münster,
  140. Nürnberg,
  141. Tübingen,
  142. Ulm,
  143. Athens,
  144. Budapest,
  145. Budapest,
  146. Kaposvár,
  147. Szolnok,
  148. Haifa,
  149. Jerusalem,
  150. Ramat Gan,
  151. Napoli, Campania
  152. Napoli, Campania
  153. Roma, Lazio
  154. Brescia, Lombardia
  155. Padova, Veneto
  156. Bari,
  157. Bergamo,
  158. Genova,
  159. Milano,
  160. Milano,
  161. Roma,
  162. Siena,
  163. Torino,
  164. Matsumoto, Nagano
  165. Chuo-ku,
  166. Hirakata-city,
  167. Seoul,
  168. Seoul,
  169. Seoul,
  170. Seoul,
  171. Nijmegen, Gelderland
  172. Amsterdam, Noord-holland
  173. Leiden, Zuid-holland
  174. Zwolle,
  175. Warszawa, Mazowieckie
  176. Warszawa,
  177. Warszawa,
  178. Lisbon, Lisboa
  179. Almada,
  180. Lisboa,
  181. Porto,
  182. Moscow,
  183. Ryazan,
  184. St. Petersburg,
  185. Bratislava,
  186. Bloemfontein, FREE State
  187. Johannesburg, Gauteng
  188. Johannesburg, Gauteng
  189. Pretoria, Gauteng
  190. Pretoria, Gauteng
  191. L'Hospitalet de Llobregat, Barcelona
  192. Malaga, Málaga
  193. Pamplona, Navarra
  194. Barcelona,
  195. Barcelona,
  196. Barcelona,
  197. Gran Canaria,
  198. La Coruna,
  199. Madrid,
  200. Madrid,
  201. Madrid,
  202. Madrid,
  203. Sevilla,
  204. Toledo,
  205. Valencia,
  206. Valencia,
  207. Lund,
  208. Zurich, Zürich (DE)
  209. Genève,
  210. Lausanne,
  211. Bornova, Izmir
  212. Adana,
  213. Ankara,
  214. Ankara,
  215. Istanbul,
  216. Bristol, Bristol, CITY OF
  217. Truro, Cornwall
  218. Brighton, EAST Sussex
  219. Chelmsford, Essex
  220. Swansea, Glamorgan
  221. Preston, Lancashire
  222. London, London, CITY OF
  223. Birmingham,
  224. Leeds,
  225. Wirral,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Official Title  ICMJE The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Brief Summary Two-arm, randomized, prospective, open-label, multi-center, phase III study to compare the efficacy and safety of MEK162 (45 mg BID) versus dacarbazine (1000 mg/m2 IV every 3 weeks) in patients with advanced (Stage IIIC) unresectable or metastatic (Stage IV) NRAS Q61 mutation-positive cutaneous or unknown primary melanoma. The mutation analysis will be performed at a central laboratory. Only those patients with Q61 mutation per central laboratory and meet all eligibility criteria will be randomized. A total of 393 patients will be randomized 2:1 to receive either MEK162 or dacarbazine. Patients will be stratified according to AJCC stage (IIIC, IVM1a, and IVM1b versus IVM1c), ECOG Performance status (0 versus 1) and any prior number of lines of immunotherapy (immunotherapies versus none). This study will use an Interactive Response Technology (IRT). The primary end point of the study is progression-free survival. Key secondary end point is overall survival
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic or Unresectable Cutaneous Melanoma
Intervention  ICMJE
  • Drug: MEK162
    MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
  • Drug: Dacarbazine
    Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
Study Arms  ICMJE
  • Experimental: MEK162
    Intervention: Drug: MEK162
  • Active Comparator: Dacarbazine
    Intervention: Drug: Dacarbazine
Publications * Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. doi: 10.1016/S1470-2045(17)30180-8. Epub 2017 Mar 9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 13, 2016)
402
Original Estimated Enrollment  ICMJE
 (submitted: January 4, 2013)
393
Actual Study Completion Date  ICMJE June 4, 2019
Actual Primary Completion Date December 1, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)
  • Presence of NRAS Q61 mutation in tumor tissue prior to randomization as determined by a Novartis designated central laboratory
  • Naïve untreated patients or patients who have progressed on or after any number of prior lines of immunotherapy for unresectable locally advanced or metastatic melanoma
  • Evidence of at least one measurable lesion as detected by radiological or photographic methods
  • Adequate bone marrow, organ function, cardiac and laboratory parameters
  • Normal functioning of daily living activities

Exclusion Criteria:

  • Any untreated CNS metastases
  • Uveal or mucosal melanoma
  • History of or current evidence of retinal vein occlusion (RVO) or risk factors of RVO
  • Patients with washout period < 6 weeks from the last dose of ipilimumab or other immunotherapy.
  • Previous systemic chemotherapy for unresectable locally advanced or metastatic melanoma.
  • History of Gilbert's syndrome
  • Prior therapy with a MEK- inhibitor
  • Impaired cardiovascular function or clinically significant cardiovascular diseases
  • Uncontrolled arterial hypertension despite medical treatment
  • HIV positive or active Hepatitis A or B
  • Impairment of gastrointestinal function
  • Patients who have undergone major surgery or radiotherapy ? 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
  • Patients with neuromuscular disorders that are associated with elevated CK.
  • Pregnant or nursing (lactating) women
  • Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study

Other protocol-defined inclusion/exclusion criteria may apply

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Austria,   Belgium,   Brazil,   Canada,   Czechia,   France,   Germany,   Greece,   Hungary,   Israel,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Poland,   Portugal,   Russian Federation,   Slovakia,   South Africa,   Spain,   Sweden,   Switzerland,   Turkey,   United Kingdom,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT01763164
Other Study ID Numbers  ICMJE CMEK162A2301
C4211002 ( Other Identifier: Alias Study Number )
2012-003593-51 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP